This contract supports the design and evaluation of innovative vaccine candidates and delivery platforms that aim to achieve durable, robust and broadly protective immunity. Activities may include immunologic analyses to inform vaccine design and identify surrogates/correlates of protection; in vitro and in vivo immunogenicity and efficacy testing; assay and reagent development; and clinical studies and trials. Additional studies are being conducted to evaluate the immune response to SARS-CoV-2 infection.